For patients with symptomatic chronic spontaneous urticaria after treatment with second-generation H1-antihistamines, administration of the oral, highly selective Bruton’s tyrosine kinase inhibitor, remibrutinib, results in a significant improvement in a composite measure of itching and hives at week 12, according to a study published in the March 6 issue of the New England Journal of Medicine.
Leave A Comment